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ABSTRACT 
Expansion of a polyglutamine-encoding trinucleotide CAG repeat in the androgen receptor 
(AR) gene causes spinal and bulbar muscular atrophy (SBMA, or Kennedy’s disease). SBMA 
is an adult-onset disease characterized by progressive muscle weakness and atrophy due to 
the degeneration of lower motor neurons in the brainstem and spinal cord. At present, 
effective disease-modifying treatment is not available for this disorder. Neuronal dysfunction 
in SBMA is at least in part due to a toxic gain of function of the mutant AR, however, the 
underlying mechanism in the pathogenesis is not known. Work in this thesis identified new 
disease features of SBMA (Study I), investigated the effect of the polyglutamine expansion 
in the context of normal AR function (Study II), and explored pharmacological strategies for 
reducing mutant AR as potential treatments (Studies III and IV).  
In Study I, we describe a 29-year old SBMA patient with a 68 CAG repeat, the largest 
reported to date. The patient had an unusually early onset and novel clinical features, 
including developmental defects and autonomic dysfunction.  
In Study II, we examined the effect of the polyglutamine expansion in the AR on 
androgen-induced differentiation of neuronal cells. We show that mutant AR expression in 
this model leads to aberrant neurite outgrowth and reduced cell cycle arrest. The expanded 
polyglutamine tract in the AR interferes with the activity of the ubiquitin ligase APC/C-Cdh1, 
a critical regulator of cell cycle exit and neuronal architecture. These findings suggest that 
cellular abnormalities due to the stabilization of APC/C-Cdh1-dependent substrates may 
contribute to the pathogenic mechanism in SBMA.  
Augmentation of insulin-like growth factor (IGF)-1/Akt signaling was previously shown 
to promote the degradation of polyglutamine-expanded AR. In Study III, we tested the 
efficacy of exogenous IGF-1 administration in a transgenic mouse model of SBMA. We 
report that systemic delivery of IGF-1 reduces mutant AR accumulation and ameliorates 
disease manifestations in SBMA mice. We also tested a novel curcumin analog in cell and 
animal models of SBMA and investigated its mechanism of action. We show in Study IV 
that this compound enhances the clearance of mutant AR and mitigates the SBMA phenotype 
in Drosophila melanogaster and mice. The protective effect of the compound on mutant AR-
induced degeneration in Drosophila is mediated through the Nrf1/Nrf2-dependent antioxidant 
response. Our results establish IGF-1 and curcumin analogs as candidates for therapeutic 
intervention in SBMA. 
In summary, our findings extend the known phenotype of SBMA. We also provide 
evidence that the mutant AR alters ubiquitin-dependent degradation pathways that are 
  
necessary for neuronal differentiation and function. Lastly, our results demonstrate the 
preclinical efficacy of IGF-1 and curcumin analogs in SBMA and warrant further 
investigation of these compounds in clinical studies.  
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1 INTRODUCTION 
 
Spinal and bulbar muscular atrophy (SBMA, or Kennedy’s disease) is an inherited, 
adult-onset degenerative disease of lower motor neurons in the brain stem and spinal 
cord. The clinical features and X-linked inheritance pattern of this disease were 
described by the physician William Kennedy in 1968 (Kennedy et al., 1968). In 1991, a 
trinucleotide CAG repeat expansion in the androgen receptor (AR) gene, a novel type 
of mutation at the time, was defined as the genetic cause of SBMA. While the length of 
this CAG repeat ranges from 9 to 36 in the general population, it is increased to 38 or 
greater in SBMA and leads to an expanded polyglutamine tract in the AR protein (La 
Spada et al., 1991).  Polyglutamine expansions in unrelated proteins were subsequently 
found to cause eight different neurodegenerative disorders, including Huntington’s 
disease, dentatorubral-pallidoluysian atrophy, and six spinocerebellar ataxias (SCA 
types 1, 2, 3, 6, 7, and 17) (Orr and Zoghbi, 2007). Today, the polyglutamine diseases 
constitute a common group of hereditary neurodegenerative disorders, and much 
progress has been made in understanding the underlying mechanisms.  
Members of the polyglutamine disease family have several similarities that reflect 
their shared type of mutation. The length of the CAG repeats in the respective genes 
shows a similar pathological threshold, inversely correlates with the age of onset, and 
tends to increase with successive generations. Despite widespread expression of the 
causative proteins, neurons appear to be particularly vulnerable to the effects of the 
mutation. Moreover, the mutant proteins accumulate in the neuronal populations that 
are susceptible to degeneration. These findings have led to the hypothesis that the 
disorders also share a common pathogenic pathway. However, each disease affects 
different subsets of neurons, which results in distinct pathology and clinical features. In 
recent years there has been an emerging realization that the protein context may play an 
important role in defining the toxicity of expanded polyglutamine tracts. This has 
prompted the investigation of the polyglutamine expansion in relation to the normal 
functions of the host proteins (Gatchel and Zoghbi, 2005). 
The identification of key pathways in the pathogenic mechanism, and the 
development of effective treatment are remaining challenges in the polyglutamine 
disease field. These two separate but interconnected themes form the basis of this 
thesis, focusing on the mutant AR protein in SBMA.  
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1.1 Clinical characterization 
SBMA becomes manifest in mid-life as progressive weakness and atrophy of bulbar 
and extremity muscles in males. Symptoms and findings include dysarthria, dysphagia, 
fasciculations, cramps, tremor, gait disturbances, and mild sensory impairment (Atsuta 
et al., 2006; Kennedy et al., 1968; Rhodes et al., 2009). In addition to the neurological 
manifestations, affected individuals often show mild signs of androgen insensitivity, 
such as gynecomastia, testicular atrophy, and reduced fertility (Arbizu et al., 1983). 
Life span is often normal in SBMA, but the disease severity can cause premature death 
due to aspiration pneumonia or respiratory failure in severely affected individuals. With 
an estimated prevalence of 1 in 40,000 worldwide, SBMA is a rare disorder. However, 
individuals with SBMA are frequently misdiagnosed with other neuromuscular, such as 
spinal muscular atrophy and amyotrophic lateral sclerosis (Rhodes et al., 2009).  
At the histopathological level, SBMA is characterized by degeneration and loss of 
motor neurons in the anterior horn of the spinal cord and brainstem motor nuclei, and of 
sensory neurons in the dorsal root ganglia (Sobue et al., 1989). Skeletal muscle biopsies 
of SBMA patients show features of both denervation and myofiber degeneration 
(Soraru et al., 2008). A hallmark of polyglutamine diseases is the presence of nuclear 
inclusions containing the mutant protein. In SBMA, nuclear inclusions containing 
mutant AR are present primarily in motor neurons, but also in other parts of the nervous 
system as well as in non-neuronal tissues including prostate, testis, liver, and skin 
(Adachi et al., 2005; Li et al., 1998a; Li et al., 1998b).   
 
1.2 The androgen receptor 
The AR is a ligand-activated transcription factor that mediates the biological actions of 
androgens, including testosterone and dihydrotestosterone. It belongs to the 
superfamily of nuclear receptors and consists of three functional domains: an amino-
terminal regulatory domain, a central DNA-binding domain, and a carboxy-terminal 
ligand-binding domain. The polymorphic polyglutamine tract is located in the amino-
terminal regulatory domain (Figure 1). In the absence of androgen, the AR localizes to 
the cytoplasm in complex with the heat shock proteins. Ligand binding causes the AR 
to dissociate from the heat shock protein complex and translocate in the nucleus, where  
it dimerizes and regulates the expression of target genes (Figure 2). Evidence suggests  
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that the AR also has non-canonical functions that are independent of its interaction with 
DNA and, instead, rely on association with signaling proteins (Matsumoto et al., 2013). 
Although not essential for life, AR is required for the development and 
maintenance of the male sexual phenotype. Full or partial loss of AR causes androgen 
insensitivity syndrome, a spectrum of developmental abnormalities that range from 
mild virilization defects to varying degrees of feminized phenotypes (Quigley et al., 
1995).  
 
1.3 Disease mechanism 
1.3.1 Lessons from animal models 
Despite the finding of androgen insensitivity in SBMA, clinical and genetic evidence 
suggested that the causative mutation in the AR leads to an abnormal gain of function, 
since loss of the AR is not associated with a neurological phenotype or weakness 
(Quigley et al., 1992). With the identification of other members of the polyglutamine 
disease family, it became clear that the repeat expansion in otherwise unrelated proteins 
is a common denominator for neurodegeneration in these disorders. Studies addressing 
the pathogenic mechanism in polyglutamine diseases have therefore focused primarily 
on the expanded polyglutamine tract. These studies showed that peptides and protein 
fragments containing long stretches of glutamines have a tendency to form insoluble  
 
 
 
 
Figure 1: Domain structure of the AR. AR belongs to the superfamily of nuclear 
receptors and consists of three functional domains: an amino-terminal regulatory 
domain, a central DNA-binding domain (DBD), and a carboxy-terminal ligand-
binding domain (LBD). The DBD and LBD are linked via a flexible hinge region, 
which contains a bipartite nuclear localization signal (NLS). The polymorphic 
polyglutamine tract (polyQ) is located in the amino-terminal regulatory domain. 
The length of this tract ranges between 9 and 36 in the normal population, and is 
38 or greater in SBMA. 
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aggregates in vitro and in vivo (Marsh et al., 2000; Ordway et al., 1997; Scherzinger et 
al., 1997). The length threshold for aggregation correlates with the threshold for disease 
in humans, indicating that aggregation may be related to the pathogenic process. 
Nuclear inclusions in autopsy material were found to stain positively only with 
antibodies with epitopes in the amino-terminal portion of the protein, including the 
polyglutamine tract (Li et al., 1998a). Similar observations were made in other 
polyglutamine diseases and suggested that pathology in these disorders might be caused 
by proteolytic products of the full-length proteins (DiFiglia et al., 1997). Caspase-
mediated cleavage of mutant AR was demonstrated in vitro (Kobayashi et al., 1998), in 
line with proteolytic processing of other polyglutamine-expanded proteins (Goldberg et 
al., 1996; Wellington et al., 1998). Such fragments are more toxic than the full-length 
proteins in cultured cells and in the fruit fly Drosophila melanogaster (Chan et al., 
2002; Merry et al., 1998), and form intracellular inclusions that closely resemble those 
found in patients (Taylor et al., 2003). 
The presence of inclusions consisting of the mutant protein in vulnerable neuronal 
populations initially suggested that they are directly responsible for toxicity in 
polyglutamine diseases (Ross and Poirier, 2004). It was subsequently shown that 
inclusions are neither necessary nor sufficient for neuronal dysfunction animal models  
(Cummings et al., 1999; Klement et al., 1998). The regional distribution of inclusions 
 
 
 
 
Figure 2: Function of the AR. In the absence of androgen, AR localizes to the 
cytoplasm in association with Hsp90. Binding of ligand to the LBD induces a 
conformational change, which causes AR to dissociate from the Hsp90 complex and 
translocate into the nucleus. Androgen-bound AR regulates the expression of target 
genes by binding to specific androgen response elements (ARE) in the DNA via the 
recruitment of transcriptional co-regulators. 
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in SBMA and other disorders does not always correspond to the selective pathology 
(Zoghbi and Orr, 2000). Detailed cellular analyses revealed a protective role for 
inclusions as part of an adaptive response that relocates toxic and aggregation-prone 
proteins to inert deposits (Arrasate et al., 2004; Taylor et al., 2003).  
The link between repeat length, aggregation, and toxicity of the polyglutamine 
tract was not sufficient to account for the differential neuronal vulnerability in different 
polyglutamine diseases. Mice expressing an amino-terminal fragment of mutant AR 
develop widespread neuronal dysfunction, without the male-limited manifestations and 
motor neuron specificity of SBMA (Abel et al., 2001). Expression of an expanded 
polyglutamine tract under the AR promoter results in a similar phenotype in mice, 
indicating that cell type specificity is not determined by the expression level and pattern 
of the mutant protein alone (Adachi et al., 2001). The lack of gender effects and lower 
motor neuron specificity in mice expressing fragments of the mutant AR suggested that 
these disease features likely require the full-length protein.  
The first attempts to model SBMA in mice using full-length human AR had 
transgenes with CAG repeat lengths ranging between 44 and 65. Although the repeat 
lengths of these constructs reflect the range seen in patients, the transgenic mice did not 
show a neurological phenotype (Bingham et al., 1995; Merry et al., 1996; La Spada et 
al., 1998). Since then, several SBMA mouse models have been developed that express 
full-length mutant AR with highly expanded CAG repeat lengths ranging from 97 up to 
121 (Chevalier-Larsen et al., 2004; Cortes et al., 2014a; Katsuno et al., 2002; 
McManamny et al., 2002; Sopher et al., 2004; Yu et al., 2006). These mice show late-
onset, progressive motor impairment and neuromuscular pathology, thus confirming 
that the full-length protein is needed to produce SBMA manifestations in this model 
system. The disease phenotype occurs only in males and can be rescued by castration, 
demonstrating a requirement for androgen in the pathogenesis (Chevalier-Larsen et al., 
2004; Katsuno et al., 2002). Toxicity of the full-length mutant AR is also ligand-
dependent in Drosophila models, with a requirement for exogenous androgen 
administration (Pandey et al., 2007; Takeyama et al., 2002). Subsequent studies have 
shown that the SBMA phenotype in mice and flies also requires nuclear localization of 
the mutant AR in addition to ligand binding (Montie et al., 2009; Nedelsky et al., 
2010). These findings demonstrate that protein context and normal AR functions are 
required for the disease phenotype in SBMA.  
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1.3.2 Molecular mechanisms  
The molecular mechanism in SBMA and other polyglutamine diseases has been subject 
to considerable debate. The polyglutamine expansion in AR leads to a slight loss of 
transactivation function in vitro (Chamberlain et al., 1994; Mhatre et al., 1993; 
Nakajima et al., 1996) but, as discussed above, this is unlikely to be the cause of 
neuronal degeneration in SBMA.  
The tendency of expanded polyglutamine proteins to form aggregates indicates 
that they might affect the distribution and function of other cellular proteins. The 
presence of ubiquitin, chaperones, and proteasome subunits in inclusions suggested that 
the proteolytic pathway might be altered in affected neurons (Cummings et al., 1998; Li 
et al., 1998a). The ubiquitin-proteasome system (UPS) is a major pathway for the 
degradation of short-lived, misfolded, and damaged proteins in the nucleus and 
cytoplasm (Hershko and Ciechanover, 1998). The activity of the UPS mediates the 
turnover of factors involved in many different cellular processes, including cell cycle 
control, transcription, signaling, and apoptosis. It was proposed that expanded 
polyglutamine proteins might impair the UPS, either directly by blocking the 
proteasome or indirectly by sequestration of essential UPS components in inclusions 
(McKinnon and Tabrizi, 2014). Inhibition of this system leads to the stabilization of 
UPS substrates, which causes cellular dysfunction and death. Although polyglutamine 
proteins can impair the ubiquitin-dependent proteolysis in cultured cells (Bence et al., 
2001; Bennett et al., 2005; Maynard et al., 2009), the UPS appears to be operative in 
mouse models of polyglutamine diseases, including SBMA (Bett et al., 2009; Bowman 
et al., 2005; Maynard et al., 2009; Tokui et al., 2009).  
Molecular chaperones are another branch within the cellular protein quality control 
machinery that have been implicated in polyglutamine diseases. Their activities are 
directed towards protein refolding, stabilizing non-native proteins, and in some cases, 
assisting proteolytic pathways such as the UPS and the lysosomal system (Gestwicki 
and Garza, 2012). Polyglutamine-expanded proteins likely place an increased demand 
on the chaperone machinery due to their tendency to aggregate. Overexpression of 
chaperones reduces the accumulation and toxicity of the mutant AR (Adachi et al., 
2003; Stenoien et al., 1999), indicating that protein quality control might be affected in 
SBMA. 
Substantial evidence suggests that the mutant AR also has effects on gene 
expression. Polyglutamine-expanded AR affects the cellular distribution of CREB-
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binding protein (CBP), NF-Y, p300/CBP-associated factor, and nuclear receptor 
coactivator 1 into inclusions and thereby may cause transcriptional dysregulation in 
cells (Katsuno et al., 2010; McCampbell et al., 2000; Stenoien et al., 1999).  
Although inclusions have been disconnected from toxicity, it is possible that 
oligomeric species may be responsible for the pathology in polyglutamine diseases. A 
study reported the presence of soluble oligomers consisting of amino-terminal 
fragments of the mutant AR in a mouse model of SBMA. The oligomers disappeared 
with castration, which halts disease progression (Li et al., 2007).  
An alternative explanation for toxicity in polyglutamine diseases is that the 
polyglutamine expansion alters existing functions of the host protein, which may lead 
to enhancement or reduction of certain activities. This hypothesis is supported by the 
finding that normal AR functions, such as ligand binding and nuclear translocation, are 
necessary for the SBMA phenotype in animal models (Montie et al., 2009; Nedelsky et 
al., 2010). In Drosophila, mutant AR-induced degeneration also requires DNA binding 
and cofactor interactions via the activation factor 2 domain (Nedelsky et al., 2010). The 
expanded polyglutamine tract is necessary, but also not sufficient for toxicity for other 
polyglutamine diseases. For example, phosphorylation can modulate the toxicity of 
mutant ataxin-1, which causes SCA1, and huntingtin, which is responsible for 
Huntington’s disease (Emamian et al., 2003; Gu et al., 2009; Humbert et al., 2002).  
It was recently shown that AR regulates the activity of the transcription factor EB 
(TFEB), which coordinates the expression of autophagy related genes (Cortes et al, 
2014b). While the non-expanded AR promoted TFEB transactivation, the mutant AR 
interfered with this function and thereby reduced autophagic flux. This result 
demonstrates that effects of the polyglutamine expansion on normal protein function 
can have wide-ranging cellular consequences. 
 
1.3.3 Role of non-neuronal tissues 
Most mechanistic studies to date have assumed cell-autonomous toxicity of mutant AR 
in motor neurons in SBMA. It is established that neurons critically depend on 
neighboring cells for proper function and survival. Accumulating evidence suggests 
that non-neuronal tissue is also affected by the mutant AR and may be important to the 
pathogenic process. Skeletal muscle provides trophic support to motor neurons and 
regulates synaptic activity and axonal function (Funakoshi et al., 1995). Muscle 
pathology in SBMA has features of both denervation and myofiber degeneration 
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(Soraru et al., 2008), and serum creatine kinase levels are higher than expected for a 
purely neurogenic disease (Guidetti et al., 1996). Furthermore, knock-in mice 
expressing AR with 113 glutamines develop myopathy in the absence of motor neuron 
death (Yu et al., 2006). Overexpression of non-expanded AR in skeletal muscle leads to 
a neuromuscular phenotype in mice that recapitulates key characteristics of SBMA, 
including gender delineation, androgen-dependence, and motor axon loss (Monks et al., 
2007). The contribution of skeletal muscle to SBMA pathogenesis was recently 
addressed with a new mouse model based on the Cre-Lox system that allows cell type-
specific excision of a mutant AR transgene. Transgene expression in this model is 
driven by the AR promoter and causes motor dysfunction and premature death in 
males. Muscle-specific abrogation of mutant AR in the mice prevented not only the 
behavioral phenotype but also degeneration of motor axons, despite the observation that 
levels of mutant AR in the spinal cord were unaffected (Cortes et al., 2014a). Together, 
these findings indicate that muscle is a primary target for mutant AR toxicity and 
contributes to motor neuron degeneration in SBMA.  
 
1.4 Therapeutic strategies 
Neuronal death in SBMA is at least in part due to a toxic gain of function of the 
polyglutamine-expanded AR. The ideal scenario for treating SBMA in the future is 
gene therapy, which involves replacement of the mutant AR gene with a healthy allele. 
Until this form of therapy becomes feasible, our next best bets are approaches that 
target the downstream consequences of the mutant AR gene. Studies in cell and animal 
models have led to important insights into the pathogenic mechanism of SBMA. Based 
on this knowledge, a number of different therapeutic approaches have been developed, 
as discussed below.  
 
1.4.1 Androgen reduction 
Androgen is critical in the pathogenesis of SBMA. Ligand binding to the AR induces 
dissociation from heat shock proteins and nuclear uptake, which are necessary steps for 
toxicity of the mutant protein (Katsuno et al., 2002; Montie et al., 2009; Nedelsky et al., 
2010). This explains why the full disease becomes manifest only in men; females, even 
if homozygous for the mutation, are protected by having low levels of circulating 
androgens (Schmidt et al., 2002). In mice, the SBMA phenotype of males is rescued by 
castration, while testosterone administration triggers the disease in females (Chevalier-
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Larsen et al., 2004; Katsuno et al., 2002). The close link between androgen and toxicity 
in SBMA indicates that the ligand-binding step of mutant AR toxicity could be a target 
for therapeutic intervention. A study in mice showed that the androgen-reducing agent 
leuprorelin, a lutenizing hormone-releasing hormone agonist that reduces testosterone 
release from the testis, prevents onset of the SBMA phenotype (Katsuno et al., 2003).  
Androgen reduction therapy in SBMA patients has been tested in three 
randomized, placebo-controlled clinical trials. The agents used in the studies were 
leuprorelin and dutasteride, a 5-alpha-reductase inhibitor, which blocks the conversion 
of testosterone into the more potent dihydrotestosterone. Neither of the two androgen-
reducing agents significantly improved primary clinical outcome measures in 
randomized, placebo-controlled studies (Fernandez-Rhodes et al., 2011; Katsuno et al., 
2010). However, leuprorelin improved swallowing parameters and decreased nuclear 
accumulation of mutant AR in scrotal skin cells after 48 weeks in a phase 2 study with 
50 patients (Banno et al., 2009). Although a subsequent phase 3 study in 200 patients 
showed no effect on swallowing function overall, there was a benefit on post hoc 
analysis in a sub-group of patients with disease duration less than 10 years (Katsuno et 
al., 2010). While the results from these studies overall were negative, there are 
indications that androgen reduction therapy reduces mutant AR accumulation and may 
modify the progression of SBMA at early disease stages.  
 
1.4.2 Antisense therapy  
Neuronal dysfunction in SBMA and other polyglutamine diseases is in large part due to 
a toxic gain of function of the repeat expansion in the respective proteins. Because the 
exact mechanism underlying the pathogenesis in these disorders remains unclear, 
reducing levels of the disease-causing proteins has emerged as a promising approach 
for treatment. Conditional mouse models of Huntington’s disease and SCA1 have 
shown that switching off the expression of the polyglutamine-expanded proteins slows 
disease progression and even reverses the pathology (Yamamoto et al., 2000; Zu et al., 
2004). These findings have prompted the investigation of gene silencing approaches 
using RNA interference (RNAi) and antisense oligonucleotide (ASO) technology in 
polyglutamine diseases. Although adverse effects with long-term gene suppression are 
a concern with this strategy, encouraging results have been obtained in mouse models 
of Huntington’s disease, SCA1, and SCA7 (Harper et al., 2005; Kordasiewicz et al., 
2012; Ramachandran et al., 2014; Xia et al., 2004), and clinical trials are planned.  
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A recent study found that AR-specific ASOs suppress mutant AR expression in vitro 
and in vivo. The ASOs reduced mutant AR accumulation and attenuated the disease 
phenotype in two different mouse models of SBMA (Lieberman et al., 2014). In 
another study, Miyazaki et al. described an indirect approach by which RNAi was used 
to regulate mutant AR transcript levels. The authors identified a microRNA (miR-196a) 
that enhances the decay of AR mRNA by silencing CELF2, an RNA-binding protein 
known to bind to, and stabilize, AU-rich sequences. Viral delivery of miR-196a 
reduced mutant AR accumulation and ameliorated the disease phenotype in SBMA 
mice (Miyazaki et al., 2012). These studies show that antisense approaches aimed at 
decreasing AR expression can modify SBMA manifestations in animal models. 
 
1.4.3 Enhancing protein clearance 
An alternative strategy for reducing levels of the mutant AR is to accelerate the 
clearance of the protein. The main route of degradation of the AR is via the UPS 
(Lieberman et al., 2002). It is not settled whether expanded polyglutamine tracts can be 
degraded by the proteasome, which preferentially cleaves after hydrophobic, basic, and 
acidic residues (Venkatraman et al., 2004; Michalik and Van Broeckhoven, 2004; 
Verhoef et al., 2002). However, there is substantial evidence in cell and animal models 
to suggest that enhancing UPS-mediated clearance of the mutant AR has a protective 
effect (Palazzolo et al., 2009; Tokui et al., 2009; Waza et al., 2005). Current 
pharmacological approaches for enhancing mutant AR degradation target primarily the 
protein quality control machinery. 
The function and stability of the AR are controlled by the heat shock protein (Hsp) 
90/Hsp70-based chaperone complex. In this complex, association with Hsp90 stabilizes 
AR, while Hsp70 regulates the degradation of client proteins through the recruitment of 
chaperone-dependent ubiquitin ligases such as C-terminus of Hsp70-interacting protein 
(CHIP) (Pratt et al., 2015). Activation of Hsp70, or inhibition of Hsp90, promotes UPS-
mediated clearance of the mutant AR (Wang et al., 2013, Thomas et al., 2006). 
Overexpression of Hsp70, Hsp40, or CHIP reduces mutant AR toxicity in cell culture 
and in vivo (Adachi et al., 2003; Adachi et al., 2007; Bailey et al., 2002; Kobayashi et 
al., 2000). Small molecules that influence the activity of this chaperone complex 
include geranylgeranylacetone and Hsp90 inhibitors, such as the geldanamycin 
derivatives 17-AAG and 17-DMAG. All three compounds were shown to effectively 
reduce mutant AR accumulation and ameliorate the disease phenotype in mice 
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(Katsuno et al., 2005; Tokui et al., 2009; Waza et al., 2005). Unfortunately, 
geldanamycin derivatives and related compounds have toxic side effects that make 
them unsuitable for the long-term treatment of chronic diseases such as SBMA (Supko 
et al., 1995). Chemical modulators of Hsp70 function may be an alternative option for 
this purpose. A recent study reported a small molecule, YM-1, that stabilizes Hsp70 in 
its ADP-bound state and promotes binding to unfolded proteins. YM-1 accelerates the 
degradation of mutant AR and rescues its toxicity in Drosophila (Wang et al., 2013). 
The efficacy of such an approach in mice remains to be determined. 
Association with co-regulators also influences the stability of AR. For example, 
AR is stabilized by interaction with the nuclear receptor coactivator 4 (NCOA4) (Hu et 
al., 2004). ASC-J9 and genistein promote the dissociation of AR and NCOA4 (Ohtsu et 
al., 2002; Qiang et al., 2013). Both compounds decrease levels of mutant AR and 
attenuate disease manifestations in mouse models of SBMA (Qiang et al., 2013; Yang 
et al., 2007).  
 
1.4.4 Reversing cellular defects 
Transcriptional dysregulation is an important downstream effect implicated in mutant 
AR toxicity in SBMA (Lieberman et al., 2002). Aberrant interactions between 
expanded polyglutamine proteins and transcription factors and coregulators have been 
described, including the histone acetylase CBP (McCampbell et al., 2000). Changes in 
the cellular acetylation status can be counteracted with histone deacetylase inhibitors, 
such as suberoylanilide hydroxamic acid and sodium butyrate, which have shown a 
benefit in various models of polyglutamine disease (Ferrante et al., 2003; Hockley et 
al., 2003; Ying et al., 2006). In SBMA mice, sodium butyrate improves the motor 
phenotype and delays disease progression, and leads to an overall increase in histone 
acetylation (Minamiyama et al., 2004). A recent report suggests that transcriptional 
dysregulation in SBMA can also be counteracted by triptans (Minamiyama et al., 
2012). Mutant AR expression is associated with upregulation of calcitonin gene-related 
peptide 1 (CGRP1), which leads to neuronal damage through stress kinase activation. 
The serotonin receptor 1B/1D receptor agonist naratriptan was shown to prevent 
transcriptional induction of CGRP1 and to ameliorate the disease phenotype in SBMA 
mice. 
In summary, a number of different approaches have been tested for therapeutic 
intervention in SBMA that target different stages of mutant AR toxicity. Androgen 
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reduction has failed to result in effective treatment in clinical trials. Therapeutics 
development would benefit from a better understanding of the pathogenic pathways in 
SBMA. The disease mechanism in SBMA, and new pharmacological strategies aimed 
at reducing the mutant AR protein are a major focus of this thesis. 
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2 AIMS 
 
The overall goal was to study the disease mechanism and explore new approaches for 
therapeutic intervention in SBMA. 
The specific aims addressed in this thesis were to: 
• Characterize the disease features in an SBMA patient with a 68 CAG repeat (Study I) 
• Investigate the effect of the polyglutamine expansion in the context of normal AR 
function (Study II) 
• Test pharmacological strategies for reducing the mutant AR as potential treatment for 
SBMA (Study III and IV) 
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3 RESULTS AND DISCUSSION 
 
This thesis attempts to address the disease mechanism of the polyglutamine disorder SBMA 
and potential treatment strategies. The studies described in this chapter span from the clinical 
examination of a patient (Study I) to experimental work in cell culture (Studies II and IV) 
and animal models (Studies III and IV). The techniques used range from live cell imaging, 
and biochemical and histological analyses of cells and tissues, to behavioural testing of 
SBMA mice.  
 
STUDY I:  Early onset and novel features in a spinal and bulbar muscular atrophy 
patient with 68 a CAG repeat 
SBMA patients typically develop weakness in their thirties or forties and have an average 
CAG repeat length of 47 in the AR gene, with 62 the largest repeat reported to date (Atsuta et 
al., 2006; Rhodes et al., 2009). Study I describes a 29-year-old male SBMA patient with a 68 
CAG repeat, who showed unusually early onset and new disease features. The patient has 
classical symptoms of SBMA such as weakness of facial and limb muscles and fatigue after 
exercise since age 18. The pronounced weakness and motor neuron involvement were 
confirmed on examination by quantitative muscle testing and magnetic resonance imaging of 
muscle. The patient also had gynecomastia, testicular atrophy, and sensory impairment. New 
findings included a congenital abnormality of the penis (chordee) and autonomic dysfunction. 
An inverse relationship between CAG repeat length and age of onset has been 
demonstrated in SBMA and other polyglutamine diseases, with longer repeat expansions 
associated with earlier onset (Orr and Zoghbi, 2007). The long CAG repeat found in the AR 
gene of this patient likely accounts for the early onset. Mutant AR accumulation has been 
demonstrated in a wide range of neuronal and non-neuronal tissues (Adachi et al., 2005), and 
it is not surprising that a longer repeat may also result in additional manifestations. Certain 
signs of mild androgen insensitivity commonly found in individuals with SBMA include 
breast enlargement and reduced fertility, but the development of male sex organs is usually 
normal (Dejager et al., 2002). Defects in genital masculinization are typically associated with 
loss of function mutations in the AR (Quigley et al., 1995), but the coding region of the AR 
gene did not contain any known variants that could explain the chordee deformity in the 
patient. AR protein levels in fibroblasts derived from this patient were comparable to those in 
control fibroblasts with CAG repeats in the normal range, suggesting that the observed 
phenotypic effects are not due to reduced expression of AR. Undermasculinized genitalia 
have previously been associated with a 44 CAG repeat in the AR gene of an eleven-year-old 
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boy (Ogata et al., 2001), indicating that the repeat expansion in the AR may be responsible 
for defects in male sexual development. 
While mutant AR toxicity in SBMA causes primarily lower motor neuron degeneration, 
other neuronal subtypes may also be affected in the disease. The patient had reduced sensory 
function, which has been documented in SBMA (Li et al., 1995; Rhodes et al., 2009; Sobue 
et al., 1989). Additional symptoms and findings include pain in the distal limbs, a decreased 
sweat response, and orthostatic tachycardia, indicating involvement of small unmyelinated 
nerve fibers. Mutant AR has been shown to accumulate in sympathetic ganglia and 
intermediolateral nuclei of the spinal cord on autopsy of SBMA patients (Adachi et al., 2005). 
Autonomic dysfunction in SBMA was also suggested by an earlier study that reported 
reduced epidermal nerve fiber density and autonomic skin denervation in skin biopsies from 
two patients (Manganelli et al., 2007). We did not find evidence for reduced epidermal nerve 
fiber density in this patient, which may be related to sampling location or fiber dysfunction 
without degeneration. Our findings extend the clinical picture of SBMA and suggest that the 
polyglutamine expansion can alter functions of AR that are important for male sexual 
development and neuronal physiology.  
 
STUDY II:  APC/C-Cdh1 dysregulation by the polyglutamine-expanded androgen 
receptor causes cell cycle reentry in spinal and bulbar muscular atrophy 
The AR is expressed in motor neurons (Matsuura et al., 1993), where it promotes sex 
differences in neuronal organization and neuromuscular function during development (Morris 
et al. 2004). In addition, the AR has important roles in neuronal regeneration. Androgens 
attenuate neuron loss (Yu, 1989) and increase the rate of motor axon regrowth as well as 
functional recovery after injury (Kujawa et al., 1989, Kujawa et al., 1991). It was previously 
shown that the AR induces differentiation and neurite outgrowth in neuronal cells at 
physiological concentrations of androgen (Brooks et al., 1998; Marron et al., 2005). In Study 
III, we examined the effect of the polyglutamine expansion in the AR on androgen-
dependent differentiation and neurite outgrowth in cultured cells. For this, we generated 
neuronal PC12 cell lines for the inducible expression of wild type or polyglutamine-expanded 
human AR. We found that cells expressing the mutant AR showed enhanced neurite 
outgrowth, but reduced arrest in the G0/G1 cell cycle phase, compared to cells expressing 
non-expanded AR in the presence of androgen. An earlier study suggested that androgen-
dependent neurite outgrowth by the AR is mediated through transcriptional induction of 
neuritin (Marron et al., 2005). We found that the wild type and mutant AR did not differ in 
their ability to transactivate a luciferase-based reporter in this cell line. We also did not detect 
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any differences in neuritin expression between the two AR types in the presence or absence 
of androgen.  
Although most functions of the AR are attributed to its role as a ligand-activated 
transcription factor (Matsumoto et al., 2013), there is evidence for non-canonical functions of 
AR in cell cycle control and neurite outgrowth through interaction with signaling proteins and 
components of the cell cycle machinery (Balk and Knudsen, 2008; Schindler et al., 2012). 
We found that the AR associates with the ubiquitin ligase anaphase-promoting 
complex/cyclosome (APC/C)-Cdh1, which has important functions in proliferating and 
postmitotic cells. APC/C-Cdh1 acts in the nucleus to cell regulate cycle progression, mitotic 
exit, and neuronal morphogenesis and function. It maintains the G0/G1 phase by preventing 
the accumulation of S phase and mitotic cyclins. APC/C-Cdh1 also targets the transcriptional 
regulators Id2 and SnoN, which drive axon growth during neuronal differentiation (Puram 
and Bonni, 2011). We found that the mutant AR retains the ability to interact with APC/C-
Cdh1. AR levels were not altered by inhibition of APC/C-Cdh1, indicating that the AR is not 
targeted for proteasomal degradation by the complex. 
Expression of the polyglutamine-expanded AR stabilized an APC/C-dependent reporter 
substrate, suggesting that the mutant AR interferes with the activity of APC/C-Cdh1. 
Consistent with previous reports, we did not observe an effect of mutant AR on general UPS 
reporter substrates (Tokui et al., 2009). This indicates that stabilization of the APC/C 
substrate is specific to this ubiquitin-dependent degradation pathway and not due to global 
inhibition of protein turnover by the polyglutamine-expanded AR. Inhibition of the APC/C-
Cdh1 complex in developing neurons leads to abnormalities in cell cycle exit, axon growth, 
and synaptic function (Lasorella et al., 2006; Konishi et al., 2004; van Roessel et al. 2004). 
APC/C-Cdh1 inhibition in mature neurons results in the accumulation of cell cycle factors, 
cell cycle reactivation, and induction of apoptosis (Almeida et al, 2005).  
Live imaging of single cells expressing mutant AR revealed that accumulation of the 
APC/C reporter occurs concomitantly with neurite outgrowth, and is followed by neurite 
retraction and cell division. The results from the longitudinal analysis suggest that both the 
aberrant neurite phenotype and the mitotic behavior of the PC12 cell model are linked to the 
inappropriate stabilization of APC/C-Cdh1 substrates. Cell cycle reactivation has been 
implicated in a number of other neurodegenerative diseases, including Alzheimer’s disease, 
Parkinson’s disease, and amyotrophic lateral sclerosis (Hernández-Ortega et al., 2011). In 
these diseases, increased immunoreactivity of mitotic cyclins and other cell cycle markers has 
been demonstrated in vulnerable neuronal populations. 
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Since both expanded and non-expanded AR variants interact with APC/C-Cdh1 without 
being targeted for proteasomal degradation, it is possible that the AR regulates the ubiquitin 
ligase complex during androgen-dependent differentiation. A regulatory function has been 
demonstrated for the retinoblastoma protein, which interacts and functionally cooperates with 
APC/C-Cdh1 during cell cycle exit (Binné et al., 2007). Protein inhibitors of the APC/C-
Cdh1 complex include Emi1 and Acm1, which compete with other substrates for binding to 
the Cdh1 adaptor (Choi et al., 2008; Enquist-Newman et al., 2008, Miller et al., 2006). Our 
ongoing work aims to characterize the interaction between AR and APC/C-Cdh1 in order to 
define the mechanism of mutant AR-mediated APC/C inhibition. We also plan to investigate 
the functional status of APC/C in other cellular models of SBMA, such as primary neuronal 
cultures and stem cell-derived motor neurons from patients. Our results indicate a non-
transcriptional role for the AR in the regulation of APC/C-Cdh1, and suggest abnormal cell 
cycle reactivation as a pathogenic mechanism in SBMA. 
 
STUDY III:  Insulin-like growth factor (IGF)-1 administration ameliorates disease 
manifestations in a mouse model of SBMA 
Posttranslational modifications are critical regulators of AR localization, function, and 
stability, and can modify the toxicity of the mutant protein. Phosphorylation of the AR at two 
Akt consensus sites, serine-215 and serine-792, blocks ligand binding, reduces nuclear 
translocation, and promotes UPS-mediated clearance of the AR (Palazzolo et al., 2007; 
Palazzolo et al., 2009). This effect can be stimulated through activation of the 
phosphoinositide 3-kinase (PI3K)/Akt pathway by IGF-1. IGF-1 decreases mutant AR 
protein levels and toxicity in cultured cells (Palazzolo et al., 2007). Overexpression of a 
muscle-specific isoform of IGF-1 in SBMA mice was previously shown to reduce mutant AR 
accumulation and attenuate the disease phenotype (Palazzolo et al., 2009). These studies 
indicated that activation of the PI3K/Akt pathway could be a suitable therapeutic approach 
for SBMA.  
In Study III we examined the therapeutic potential of exogenous IGF-1 administration 
in SBMA mice. Since IGF-1 has a short half-life in vivo, we used the compound mecasermin 
rinfabate (Iplex), which consists of human recombinant IGF-1 in complex with the IGF-1 
binding protein 3 (INSMED Corporation, Richmond, VA, USA). Iplex has improved 
pharmacokinetics and reduced adverse effects compared to IGF-1 alone and was approved by 
the U.S. Food and Drug Administration for treatment of primary IGF-1 deficiency 
(Camacho-Hübner et al., 2006). We tested Iplex in a well-characterised mouse model of 
SBMA that expresses a transgene consisting of full-length human mutant AR with 97 
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glutamine residues (Katsuno et al., 2002). Toxicity of the mutant AR protein in these mice is 
androgen-dependent and associated with nuclear accumulation in motor neurons and skeletal 
muscle tissues. The disease phenotype includes progressive muscle weakness, weight loss, 
and premature death. To reflect the situation in symptomatic patients, treatment of the mice 
was started after disease onset. We found that systemic IGF-1 administration improved motor 
function, body weight, neuromuscular pathology, and survival of the SBMA mice. IGF-1 
treatment increased Akt activation and reduced mutant AR accumulation in skeletal muscle 
of the mice. No changes in Akt activation and mutant AR protein levels were detected in the 
spinal cord, indicating that amelioration of the disease phenotype in the mice was mediated 
through effects of IGF-1 in peripheral tissues.  
Accumulation of the mutant AR is widespread in neuronal and non-neuronal tissues in 
SBMA patients (Adachi et al., 2005; Li et al., 1998a; Li et al., 1998b). Recently it was 
demonstrated that systemic delivery of AR-specific ASOs improves the SBMA phenotype in 
mice more than intracerebroventricular administration (Lieberman et al., 2014), indicating 
that non-neuronal cell types contribute to neuronal degeneration in the disease. Increasing 
evidence suggests a role for skeletal muscle in the pathogenesis of SBMA (Cortes et al., 
2014a; Soraru et al., 2008; Yu et al., 2006). Motor neurons rely on muscle for trophic support 
that is critical for neuronal survival, synaptic activity, and axonal function (Funakoshi et al., 
1995). For example, brain-derived neurotrophic factor released from muscle can be taken up 
and transported in a retrograde manner by motor neurons (DiStefano et al., 1992). The 
expression of growth factors and neurotrophins in muscle is altered in SBMA mouse models 
and patients (Sopher et al., 2004; Yamamoto et al., 1999; Yu et al., 2006). Treatment with 
vascular endothelial growth factor (VEGF) was shown to reduce mutant AR toxicity in a 
neuronal cell model (Sopher et al., 2004). These findings suggest that exogenous IGF-1 
restores trophic support to motor neurons by targeting mutant AR in muscle. 
Activation of the PI3K/Akt pathway by IGF-1 also has other effects in muscle that are 
unrelated to mutant AR degradation. Akt promotes muscle hypertrophy through activation of 
mammalian target of rapamycin (mTOR) (Bodine et al., 2001; Rommel et al., 2001) and 
inhibition of glycogen synthase kinase 3 beta (Cross et al., 1995). Akt also prevents the 
expression of atrophy-related genes such as atrogin-1 and MuRF1 through inactivation of 
FOXO transcription factors (Sandri et al., 2004; Stitt et al., 2004; Zhao et al., 2007). In 
addition, IGF-1 has been shown to activate the proliferation of satellite cells, which are 
responsible for muscle regeneration (Musaro et al., 2001). It is likely that IGF-1 ameliorates 
the SBMA phenotype through both mutant AR-dependent and -independent effects on 
muscle. 
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IGF-1 can also act directly on motor neurons to promote sprouting, axonal growth, and 
survival (Caroni and Grandes, 1990). Approaches that increase the uptake of IGF-1 into the 
nervous system may therefore have an additional therapeutic benefit. Recently, it was shown 
that localized transfer of serum IGF-1 across the blood-brain barrier is stimulated by neuronal 
activity (Nishijima et al., 2010). This raises the possibility that the beneficial effect of IGF-1 
in SBMA may be enhanced in combination with physical exercise. Our results helped to 
establish IGF-1 as a therapeutic strategy for SBMA and provided the basis for clinical studies 
that are now underway. 
 
STUDY IV:  A small-molecule activator of Nrf1 and Nrf2 mitigates polyglutamine 
toxicity in SBMA models 
Curcumin is a naturally occuring polyphenol with pleiotropic biological properties, including 
anti-inflammatory and neuroprotective activities. Structural analogs of curcumin have been 
evaluated in SBMA due to their ability to disrupt AR-cofactor interactions (Ohtsu et al., 
2002; Yang et al., 2007). ASC-J9, or dimethylcurcumin, was previously shown to ameliorate 
the disease phenotype of SBMA mice by promoting the degradation of mutant AR (Yang et 
al., 2007). In Study IV we showed that a new, orally available curcumin analog, ASC-JM17, 
enhances the clearance of AR by the UPS. Treatment with the compound reduced mutant AR 
accumulation and mitigated the SBMA phenotype in cell, fly, and mouse models.  
Recently, curcumin analogs have emerged as regulators of the protein homeostasis 
network (Alavez et al., 2011; Calamini et al., 2012), which regulates protein synthesis, 
folding, transport, and degradation. This network is controlled by several signaling pathways 
that help to alleviate damage in response to extrinsic and intrinsic stressors (Balch et al., 
2008). The antioxidant response and heat shock response are important regulators of the 
protein homeostasis network. The antioxidant response is mediated by Nrf1/nuclear factor 
(erythroid-derived 2)-like 1 (NFE2L1) and Nrf2/NFE2L2, which belong to the cap’n’collar 
family of basic leucine zipper transcription factors. Nrf1 and Nrf2 regulate the expression of 
proteasome subunits and antioxidant enzymes, respectively (Radhakrishnan et al., 2010; 
Kensler et al., 2007). The heat shock response, mediated by heat shock factor 1 (Hsf1), leads 
to the induction of molecular chaperones (Pirkkala et al., 2001). We found ASC-JM17 to be a 
potent activator of the antioxidant response and heat shock responses in various cell lines. It 
increased the expression of proteasome subunits, antioxidant enzymes, and molecular 
chaperones in cell culture and in the SBMA mice. Treatment with ASC-JM17 reduced 
mutant AR accumulation, increased proteasome activity, and improved resistance to 
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oxidative stress. These findings establish ASC-JM17 as a small-molecule activator of cellular 
systems controlling protein folding, degradation, and redox balance.  
Our results showed that overexpression of the Drosophila Nrf1 and Nrf2 ortholog CncC 
or Hsf1 rescued mutant AR-induced eye degeneration in flies, indicating that both the 
antioxidant pathway and heat shock response are protective in this model. Levels of Hsf1 
were previously shown to influence the extent and distribution of mutant AR accumulation in 
SBMA mice (Kondo et al., 2013). Several Hsf1 targets, such as Hsp70, Hsp40, and Hsp27, 
reduce mutant AR protein levels and toxicity in cell and animal models (Adachi et al., 2003; 
Adachi et al., 2007; Bailey et al., 2002; Kobayashi et al., 2000). Chemical activators of the 
heat shock response ameliorate SBMA manifestations in mouse models (Katsuno et al., 2005; 
Tokui et al., 2009; Waza et al., 2005). Interestingly, knockdown of CncC, but not Hsf1, 
blocked the protective effect of ASC-JM17 on AR-induced degeneration in flies.  
Two recent reports indicate that increasing proteasome activity promotes the degradation 
of aggregation-prone proteins. A recent study reported reduced aggregation of a 
polyglutamine protein in the nematode worm Caenorhabditis elegans overexpressing the 
proteasome subunit Rpn6/Psmd11, which increases proteasome activity (Vilchez et al., 
2012). Inhibition of Usp14, a proteasome-associated deubiquitylating enzyme, accelerates 
proteasomal degradation of disease-linked proteins, such as polyglutamine-expanded ataxin-3 
(Lee et al., 2010). These findings suggest that Nrf1 may be a promising therapeutic target in 
neurodegenerative diseases due to its ability to enhance proteasome function in cells 
(Radhakrishnan et al., 2010). Increased expression of antioxidant enzymes via Nrf2 may also 
contribute to the cytoprotective effects of ASC-JM17 in SBMA, since our results indicate that 
the Nrf2 pathway is altered in the SBMA mouse model. However, It will be important to 
dissect the individual contributions of Nrf1 and Nrf2 in SBMA. 
Several lines of evidence suggest that the protective effect of the antioxidant pathway is 
not limited to SBMA. Activation of CncC was recently shown to reduce manifestations in a 
Drosophila model of alpha-synuclein toxicity (Barone et al., 2011). Furthermore, the cellular 
response to oxidative stress is impaired in models of Huntington’s disease and amyotrophic 
lateral sclerosis (Jin et al., 2013; Kirby et al., 2005). Overexpression of Nrf2 prevented motor 
neuron loss in a mouse model of amyotrophic lateral sclerosis (Vargas et al., 2008). These 
findings suggest that small-molecule activators of the Nrf1/Nrf2 pathway may be broadly 
applicable for the treatment of neurodegenerative disorders. Our findings identify the 
antioxidant pathway as a modifier of mutant AR toxicity and highlight the therapeutic 
potential of the new curcumin analog ASC-JM17 in SBMA.  
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4 CONCLUDING REMARKS 
 
A polyglutamine expansion in the nuclear hormone receptor AR causes SBMA, an adult-
onset progressive neuromuscular disorder. The key pathways leading to neuron and muscle 
degeneration in SBMA are still unknown, and effective disease-modifying treatment is 
currently not available. Work in this thesis (i) characterized new disease features, (ii) 
investigated molecular mechanisms in SBMA, and (iii) tested pharmacological approaches 
for reducing mutant AR in animal models.  
The results of Studies I and II link the polyglutamine expansion in the AR to alterations 
of normal functions. The 68 CAG repeat not only became manifest in early onset in the 
SBMA patient in Study I, as expected for such an unusually long repeat, but also in a more 
severe phenotype. New disease features included abnormal sexual development and 
autonomic dysfunction. While the additional neurological findings suggest a toxic gain of AR 
function, the developmental defect in this patient is consistent with a loss of function 
(Quigley et al., 1995). The polyglutamine expansion might cause a conformational change in 
the AR protein that enhances both gain and loss of function. In Study II, we identified a new 
role of the AR in the regulation of the ubiquitin ligase complex APC/C-Cdh1. The mutant 
AR retained the ability to associate with this complex, but negatively impacted its function. A 
recent study showed that the expanded polyglutamine tract in AR interferes with TFEB in a 
similar manner (Cortes et al., 2014b). These observations are consistent with the idea that the 
polyglutamine expansion leads to changes in existing protein interactions. The findings of 
reduced APC/C-Cdh1 and TFEB activity in SBMA models also indicates that the mutant AR 
has pleiotropic effects on cellular protein homeostasis.   
In Studies III and IV we demonstrate the preclinical efficacy of two agents that promote 
the degradation of mutant AR, IGF-1 and a curcumin analog, in an SBMA mouse model. Our 
observations also indicate that peripheral tissues can be targeted in the disease. The 
significant amelioration of the phenotype in SBMA models with these agents warrants further 
investigation in clinical studies. Studies II and IV also revealed new potential therapeutic 
targets in SBMA. The finding of cell cycle reactivation in a cellular model of SBMA suggests 
that cell cycle inhibitors may counteract mutant AR toxicity in this disease (Study II). 
However, further work in other model systems is needed to evaluate the contribution of this 
phenomenon to the pathogenic mechanism in SBMA. The identification of the Nrf1/Nrf2-
mediated antioxidant response as a modifier of mutant AR toxicity (Study IV) opens the 
possibility to repurpose existing drugs that are known activators of this pathway for the 
treatment of SBMA. Dimethyl fumarate, used clinically for the treatment of multiple 
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sclerosis, is a small-molecule activator of the antioxidant response (Ashrafian et al., 2012; 
Kappos et al., 2008). Dimethyl fumarate was recently shown to be protective in a mouse 
model of Huntington’s disease (Ellrichmann et al., 2011). Our results in cell culture and 
animal models indicate that this compound might be effective in SBMA.  
In conclusion, this thesis provides new insights into how the polyglutamine expansion 
alters normal AR functions and it offers new opportunities for therapeutic intervention in 
SBMA.  
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